Thinking of psoriasis and atopic dermatitis as a spectrum, rather than separate diseases might lead to better understanding, and potentially better treatments.
Biologic Treatments for Moderate to Severe Atopic Dermatitis
Ocular comorbidity risk is already high in patients with atopic dermatitis and may increase even further as biologic agents are introduced, a study shows.
Until recently, atopic dermatitis treatments were primarily limited to topical corticosteroids and systemic immunosuppressants.
Now, two new therapies have reached clinical practice. Nineteen more are in development.
Dupilumab given concomitantly with topical corticosteroids significantly improved signs and symptoms of atopic dermatitis (AD) in adults refractory to or intolerant of cyclosporine A, a study shows.
Early trial results show a significant reduction of itch with the oral NK-1 antagonist serlopitant
Dupilumab plus topical corticosteroids safe and effective after failure of cyclosporine in moderate-to-severe atopic dermatitis
There are two pathways that lead to atopic dermatitis. Their origins differ, but they both impair the immune system and skin barrier in AD.
An experimental drug designed to control itching in people with moderate-to-severe AD shows promise in early trial.
A new study shows that mutations in the gene CARD11 are associated with severe atopic disease.
Patients with severe atopic dermatitis who have lower serum vitamin D levels have a high sensitivity to house dust mites which can aggravate their condition, a new study shows.